About Renalytix AI
Renalytix AI is an artificial intelligence-enabled in vitro diagnostics company focused on improving the clinical management of kidney disease to enhance patient outcomes and reduce healthcare costs. The company’s primary product, KidneyIntelX, is a diagnostic platform that utilizes a proprietary AI-enabled algorithm. This algorithm integrates diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (EHR) systems, to generate a unique patient risk score. This score helps predict progressive kidney function decline in individuals with chronic kidney disease (CKD), allowing physicians and healthcare systems to optimize treatment and allocate clinical resources more effectively to high-risk patients.
KidneyIntelX is particularly focused on diabetic kidney disease (DKD), which accounts for nearly 40% of CKD cases. The test has received FDA approval and Medicare reimbursement, and the company is actively expanding its reach through partnerships with healthcare providers and insurers. Renalytix AI aims to transform kidney disease risk assessment and clinical management by providing early detection and intervention capabilities, ultimately striving to lower healthcare costs and improve the quality of life for patients.
Focus Areas
Business Intelligence
| Technology | KidneyIntelX, an AI-enabled in vitro diagnostics platform that utilizes a proprietary machine learning algorithm (random forest) to combine blood-based biomarkers (sTNFR1, sTNFR2, KIM1), inherited genetics, and electronic health record (EHR) data to generate a patient risk score for progressive kidney function decline. |
What Physicians Need to Know
For physicians, Renalytix AI's KidneyIntelX.dkd offers a powerful tool to identify patients with type 2 diabetes and early-stage chronic kidney disease who are at high risk of rapid kidney function decline. This allows for earlier, guideline-recommended treatment and intervention, potentially slowing disease progression and improving patient outcomes. The test provides an easy-to-understand risk score with specific clinical recommendations, helping to optimize patient treatment and compliance. The integration of blood biomarkers and EHR data provides a comprehensive risk assessment that goes beyond traditional kidney function markers. This precision medicine approach can help physicians make informed decisions about patient management, including medication adjustments (e.g., SGLT2 inhibitors), lifestyle interventions, and timely referrals to specialists.
Renalytix AI's KidneyIntelX.dkd integrates data from blood-based biomarkers and electronic health records (EHR) using AI-enabled algorithms. They have established partnerships with healthcare systems and digital health companies like Carna Health and Tempus AI to expand access and integrate their testing into existing clinical workflows. This allows for electronic reporting of patient results to ordering clinicians and patient portals. Collaborations with academic medical centers like Mount Sinai, Emory University, and the University of Pennsylvania have been crucial for clinical validation and data generation.
What the Web Says
Renalytix AI is a healthcare technology company that utilizes artificial intelligence to improve kidney disease diagnosis and management, primarily through its KidneyIntelX platform. The company's main product, KidneyIntelX.dkd, is an FDA-authorized prognostic test that identifies patients at risk for progressive decline in kidney function, especially those with Type 2 diabetes and early-stage chronic kidney disease. While there's enthusiasm for its innovative technology and potential to improve patient outcomes and reduce healthcare costs, some employer reviews suggest challenges with senior management and a potentially unhealthy work environment.
Overall: MixedStrengths
- Innovative AI-powered diagnostic platform for kidney disease.
- FDA authorization for KidneyIntelX.dkd.
- Potential to improve patient outcomes and lower healthcare costs.
- Strong partnerships, including with Mount Sinai Health System.
- Employees are excited about contributing to game-changing technology.
- Remote work philosophy and comprehensive benefits for US employees.
Limitations
- Some employer reviews mention an unhealthy work environment.
- Concerns about absentee leadership and incompatible senior management.
- Lengthy FDA review process for KidneyIntelX.
- Limited information available on G2, Glassdoor, and Capterra specifically for Renalytix AI product reviews.
- Reddit discussions primarily focus on stock performance and investment potential rather than product or employer experience.
Based on reviews from: G2.com, LWW.com, Ovid.com, FierceBiotech.com, Investing.com, Renalytix.com, MedTechDive.com, Reddit.com, Indeed.com, AnnualReports.com, Capterra.com, Trustpilot.com
Last updated: 2026-10-29
Videos
News, demos, and interviews about Renalytix AI.
Videos load interactively. If none appear, search YouTube for Renalytix AI →
Press & Coverage
Frequently Asked Questions
Related Companies
AIRA Matrix is a healthcare AI company that develops cutting-edge artificial intelligence solutions for life sciences applications, with a strong emphasis on deep learning for medical image analysis. Their innovative products and services are designed to enhance diagnostic accuracy, improve workflow efficiency, and reduce turnaround times in pathology laboratories. The company provides diagnostic, prognostic, and […]
AI-LabTest is a secure, AI-powered digital health platform designed to help individuals understand their medical lab reports. The platform analyzes uploaded bloodwork or diagnostic results (in PDF, JPG, or TXT formats) and translates complex medical data into clear, personalized summaries. These summaries highlight key findings, potential implications, and practical next steps in patient-friendly language. The […]
Google DeepMind is a British-American artificial intelligence (AI) research laboratory and a subsidiary of Alphabet Inc.. Formed in April 2023 through the merger of DeepMind and Google AI’s Google Brain division, the company focuses on advancing artificial general intelligence (AGI) and developing AI systems for widespread public benefit and scientific discovery. Their work involves an […]
Tempus AI, Inc. is an American health technology company that utilizes data and artificial intelligence to deliver precision medicine services. The company was founded with the mission to bring data-driven precision medicine into routine care, initially focusing on oncology. Tempus has developed a platform that sequences tumor samples and employs AI models to assist physicians […]
SureMediks, a product of Rasimo Systems, LLC, is an AI-powered Clinical Operating System designed for longitudinal care, aiming to transform episodic healthcare into continuous, intelligent, and personalized patient management. The platform integrates patients, healthcare providers, clinical protocols, AI, connected medical devices, and electronic medical records into a unified ecosystem. SureMediks processes continuous real-world patient data […]
SigXA is a healthcare AI company that specializes in ambient AI medical scribe and assistant technology. Their platform captures clinician-patient conversations and converts them into structured clinical notes, which can then be pushed to Electronic Health Record (EHR) systems such as Epic, Cerner, Athenahealth, DrChrono, and eClinicalWorks. The AI is designed to understand medical context […]